

Cannabidiol with venlafaxine in generalized anxiety, hyperhidrosis and over-active bladder

Canabidiol associado à venlafaxina em ansiedade generalizada, hiperidrose e síndrome da bexiga hiperativa

Rubens Pitliuk¹, Tatyanny Paula Pinto da Costa Santos Fucci²

Dear editor,

Efficacy reports of cannabidiol (CBD) in anxiety are widely known. Laboratory results in animals, as well as in healthy volunteers and patients with anxiety disorders support the hypothesis of CBD as a new drug with anxiolytic properties¹.

Generalized anxiety disorder (GAD) is one of the most underdiagnosed psychiatric disorders. It includes persistent and excessive preoccupation and physical symptoms related to autonomic hyperactivity and muscle tension. Frequent symptoms are tachycardia, hyperhidrosis, insomnia, fatigue, muscle pain, and difficulty to relax².

Overactive bladder syndrome (OAB) has been associated with mild, moderate and/or severe anxiety symptoms³.

In 2022 we reported unexpected improvement of hyperhidrosis with CBD in two patients⁴.

Pitliuk et al. (2022)⁵ described a 50% reduction of nocturia episodes with CBD in treatment resistant OAB.

In this letter we describe an important improvement of Hyperhidrosis and OAB in a patient with GAD.

Female, 28-year-old patient. Since adolescence, severe GAD, hyperhidrosis, OAB. She underwent several treatments without significant results. Among others, escitalopram, duloxetine, and oxybutynin.

Treatment started with venlafaxine 75mg *quaque* die. She had a marked improvement of GAD, without any improvement of OAB and hyperhidrosis.

We added *Full Spectrum CBD* with 0.3% THC. She showed a very strong and lasting improvement of hyperhidrosis and OAB. In her words: "*for the first time since I remember, my hands are dry and I do not need to carry a towel with me*", "*I needed to urinate 15 times a day now it is only 5 times*".

We maintained the treatment with Venlafaxine 75mg qd, *Full Spectrum CBD* with 0.3% THC, dose of 25mg bid.

This case confirms other observations of efficacy of CBD in OAB and hyperhidrosis even without improvement of GAD.

The association venlafaxine and CBD can be an additional treatment option in these conditions.

AUTHOR'S CONTRIBUTION:

The related authors declare to have participated equally and effectively in the manuscript's idealization, elaboration, and revision.

COPYRIGHT

Copyright© 2021 Pitliuk et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original article is properly cited.

¹ Psychiatrist - Hospital Israelita Albert Einstein. São Paulo, SP, Brazil.

² Nutritionist autonomous. São Paulo, SP, Brazil.

Associate Editor Responsible:

Agnaldo Soares Lima
Faculdade de Medicina da Universidade Federal de Minas Gerais
Belo Horizonte/MG, Brazil
Diretor Científico da Associação Médica de Minas Gerais
Belo Horizonte/MG, Brazil

Corresponding Author:

Rubens Pitliuk
Private practice - Rua Japiçóia, 145 - 05455-060 - São Paulo, SP, Brazil.
Tel.: +55 11 3022-2195
Email: rubensp@einstein.br; rubens@mentalhelp.com

Supporting sources:

Cannabidiol oil with 0.3% Tetrahydrocannabinol Full Spectrum (Hempflex3000) was provided free of charge by Greencare Company.

Conflicts of interest:

The authors declare no conflicts of interest.

Date of Receipt: September 28, 2022

Date of Accept: October 08, 2022

Publishing Date: January 31, 2023

DOI: 10.5935/2238-3182.2022e32502

REFERENCES

1. Schier ARM, Ribeiro NPO, Oliveira e Silva AC, Hallal JEC, Crippa JAS, Nardi AE, et al. Cannabidiol, a *Cannabis sativa* constituent, as an anxiolytic drug. *Braz J Psychiatry*. 2012 Jun;34(Suppl 1):104-10. DOI: <https://doi.org/10.1590/S1516-44462012000500008>
2. Zuardi AW. Basic features of generalized anxiety disorder. *Medicina (Rib Preto)*. 2017 Fev;50(Suppl 1):51-5. DOI: <https://doi.org/10.11606/issn.2176-7262.v50isupl1.p51-55>
3. Alves AT, Jácomo RH, Gomide LB, Garcia PA, Bontempo APS, Karnikoski MGO, et al. Relationship between anxiety and overactive bladder syndrome in older women. *Rev Bras Ginecol Obstet*. 2014 Jul;36(7):310-4. DOI: <https://doi.org/10.1590/SO100-7203201400050008>
4. Pitliuk R, Coelho CMF, Fucci TPPCS. Unexpected improvement of hyperhidrosis with cannabidiol. *Einstein (São Paulo)*. 2022 Feb;20:eRC5795. DOI: https://doi.org/10.31744/einstein_journal/2022RC5795
5. Pitliuk R, Czeresnia CE, Coelho CMF, Lorenzetti MD, Fucci TPPCS. Cannabidiol in the treatment of refractory overactive bladder: cases report. *Int J Health Sci [Internet]*. 2022 Jan; [cited 2022 Aug 24]; 2(1):2-4. Available from: https://www.researchgate.net/publication/357932129_Cannabidiol_in_the_treatment_of_Refractory_Overactive_Bladder_cases_report



This is an open access article distributed under the terms of the Creative Commons Attribution License.